172 related articles for article (PubMed ID: 25115206)
1. [Hyperglycaemia during treatment with everolimus].
Opdam FL; Huitema AD; Beijnen JH; Schellens JH
Ned Tijdschr Geneeskd; 2014; 158():A7544. PubMed ID: 25115206
[TBL] [Abstract][Full Text] [Related]
2. Everolimus: side effect profile and management of toxicities in breast cancer.
Paplomata E; Zelnak A; O'Regan R
Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
[TBL] [Abstract][Full Text] [Related]
3. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
Martinet W; De Loof H; De Meyer GRY
Atherosclerosis; 2014 Apr; 233(2):601-607. PubMed ID: 24534455
[TBL] [Abstract][Full Text] [Related]
5. Are we missing the mTOR target in breast cancer?
Johnston SR
Breast Cancer Res Treat; 2011 Aug; 128(3):607-11. PubMed ID: 20953834
[No Abstract] [Full Text] [Related]
6. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
7. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
8. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Johnston PB; Inwards DJ; Colgan JP; Laplant BR; Kabat BF; Habermann TM; Micallef IN; Porrata LF; Ansell SM; Reeder CB; Roy V; Witzig TE
Am J Hematol; 2010 May; 85(5):320-4. PubMed ID: 20229590
[TBL] [Abstract][Full Text] [Related]
9. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.
Tobinai K; Ogura M; Maruyama D; Uchida T; Uike N; Choi I; Ishizawa K; Itoh K; Ando K; Taniwaki M; Shimada N; Kobayashi K
Int J Hematol; 2010 Nov; 92(4):563-70. PubMed ID: 20972652
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
Slomovitz BM; Lu KH; Johnston T; Coleman RL; Munsell M; Broaddus RR; Walker C; Ramondetta LM; Burke TW; Gershenson DM; Wolf J
Cancer; 2010 Dec; 116(23):5415-9. PubMed ID: 20681032
[TBL] [Abstract][Full Text] [Related]
12. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.
Yardley DA
Clin Breast Cancer; 2014 Oct; 14(5):297-308. PubMed ID: 25065566
[TBL] [Abstract][Full Text] [Related]
13. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
Peddi PF; Shatsky RA; Hurvitz SA
Cancer Treat Rev; 2014 Mar; 40(2):320-6. PubMed ID: 24011786
[TBL] [Abstract][Full Text] [Related]
14. Everolimus in renal cell carcinoma.
Wang Y
Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in the treatment of hormone receptor-positive breast cancer.
Chavez-MacGregor M; Gonzalez-Angulo AM
Expert Opin Investig Drugs; 2012 Dec; 21(12):1835-43. PubMed ID: 22994502
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of everolimus in renal cell cancer.
Amato R; Stepankiw M
Expert Opin Pharmacother; 2013 Jun; 14(9):1229-40. PubMed ID: 23578333
[TBL] [Abstract][Full Text] [Related]
17. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Hadji P; Coleman R; Gnant M
Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
[TBL] [Abstract][Full Text] [Related]
18. Response and acquired resistance to everolimus in anaplastic thyroid cancer.
Wagle N; Grabiner BC; Van Allen EM; Amin-Mansour A; Taylor-Weiner A; Rosenberg M; Gray N; Barletta JA; Guo Y; Swanson SJ; Ruan DT; Hanna GJ; Haddad RI; Getz G; Kwiatkowski DJ; Carter SL; Sabatini DM; Jänne PA; Garraway LA; Lorch JH
N Engl J Med; 2014 Oct; 371(15):1426-33. PubMed ID: 25295501
[TBL] [Abstract][Full Text] [Related]
19. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
20. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Peterson ME
Support Care Cancer; 2013 Aug; 21(8):2341-9. PubMed ID: 23686401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
